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Summary
Background: Nicorandil is a vasodilator that both opens potassium channels and has nitrate
effects. The administration of nitrate is the gold standard for the treatment of acute heart
failure (AHF). However, there have been few reports regarding the usefulness of nicorandil for
the treatment of AHF. Therefore, we evaluated the efﬁcacy of intravenous administration of
nicorandil in patients with AHF.
Methods: A total of 31 AHF patients were enrolled, and randomized into either the nico-
randil group (n = 16) or control group (n = 15). Nicorandil was started with a bolus injection
of 100g/kg, and the continuous injection of 60—100g/kg/h within 30min after admission,
which continued for 5 days. There were no limitations in the treatment of AHF except for
nicorandil use. B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT-pro-BNP) were
measured on admission (Day 1), Day 3, and Day 7.
Results: BNP signiﬁcantly decreased in the nicorandil group on Day 3 (502.4± 406.9 pg/ml) from
Day 1 (1397.0± 1617.5 pg/ml), however, no signiﬁcant decrease was observed in the control
group. NT-pro-BNP tended to decrease on Day 3 (7316.7± 10,187.5 pg/ml, p = 0.06) and signif-
(5702.9± 6468.8 pg/ml) from Day 1 (11,270.0± 12,388.5 pg/ml) inicantly decreased on Day 7
the nicorandil group, however there were no changes in the control group. When patients from
nicorandil group were classiﬁed into a high systolic blood pressure (SBP) group (baseline SBP
>140mmHg, n = 10) and low SBP group (baseline SBP <140mmHg, n = 6), a signiﬁcant decrease
was observed in SBP from Day 1 to Day 3 in both groups.
∗ Corresponding author. Tel.: +81 476 99 1111; fax: +81 476 99 1911.
E-mail address: s6042@nms.ac.jp (A. Shirakabe).
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Conclusions: Intravenous administration of nicorandil can decrease serum cardiac stress markers,
and was shown to be effective in AHF patients. Furthermore, nicorandil improved the hemody-
namics in the patients with high SBP, and the drug could be safely administered to AHF patients
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Clinical evaluationwith low SBP.
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atients with acute heart failure (AHF) present with a form
f hypoxemic acute respiratory failure caused by acute pul-
onary edema, which gradually or rapidly changes into the
igns and symptoms of heart failure (HF). The guidelines
ublished by the European Society of Cardiology indicate
hat pharmacotherapy with vasodilators is more frequently
ecommended than ionotrophic agents in patients with-
ut excessively low blood pressure (BP) [1]. Nitrates have
een used as the gold standard for the treatment of
HF during its acute phase, however there have been
ew reports regarding the efﬁcacy of using nicorandil [N-
2-hydroxyethyl) nicotinamide nitrate] for AHF. Nicorandil
as both nitrate-like properties and activates adenosine
riphosphate-sensitive potassium channels to result in bal-
nced venous and arterial vasodilation [2]. Several studies
hat used invasive pulmonary artery catheter monitoring
ave suggested that intravenous bolus administration of
icorandil might produce optimal beneﬁts for chronic HF
atients by improving the hemodynamics [3,4]. In a more
ecent study, Minami et al. [5] reported the efﬁciency
f nicorandil for the treatment of the urgent phase of
HF by using noninvasive echocardiac hemodynamic eval-
ation.
Measurement of plasma B-type natriuretic peptide (BNP)
nd N-terminal pro-BNP (NT-pro-BNP) is useful for differen-
iating dyspnea due to AHF from dyspnea related to other
actors [6—8]. In fact, these markers are presented in guide-
ines as class I to be used in the acute setting to rule out or
o conﬁrm the diagnosis of HF [9]. BNP and NT-pro-BNP are
ecreted by the heart in response to increases in volume
xpansion or pressure overload [10]. In a previous study, the
eft ventricular end diastolic pressure and left ventricular
jection fraction (LVEF) were conﬁrmed as prognostic mark-
rs inﬂuencing BNP and NT-pro-BNP in the aortic root and
oronary sinus [11,12].
We hypothesized that nicorandil can reduce preload and
fter-load in the treatment of AHF, thus resulting in a
educed ﬁlling volume and improved cardiac output. No
revious study has evaluated the difference in the time-
ependent changes in BNP and NT-pro-BNP following the
se of nicorandil for AHF. We therefore evaluated the
atient response of BNP and NT-pro-BNP by the intra-
enous administration of nicorandil during the acute phase
f AHF, while also evaluating the acute efﬁciency of nico-
andil.
ethodsubjects
hirty-one patients with AHF who were admitted to the
ntensive care unit of Chiba Hokusoh Hospital, Nippon Med-
T
L
tology. Published by Elsevier Ireland Ltd. All rights reserved.
cal School between August 2008 and March 2009 were
nrolled in this prospective study. AHF was deﬁned as either
ew-onset HF or decompensation of chronic HF with symp-
oms sufﬁcient to warrant hospitalization [13]. HF was
iagnosed based on the Framingham criteria for a clinical
iagnosis of HF, based on the satisfaction of 2 major crite-
ia or 1 major and 2 minor criteria [14]. All patients had
New York Heart Association (NYHA) functional class of
ither III or IV. The patients were excluded if they had acute
oronary syndrome, severe renal failure on hemodialysis,
ystolic BP <80mmHg, an acute infection, or chronic liver
isease.
rocedures
he AHF patients were reciprocally randomized into either
he nicorandil (n = 16) or the control group (n = 15). Nico-
andil was started with an intravenous bolus injection of
00g/kg, and then continuous injection of 60—100g/kg/h
ithin 30min after admission, which continued for 5 days.
here was no limitation in HF therapy except the nicorandil
se, and the treatment strategy was chosen by each of
he doctors. All efﬁcient treatments for AHF (e.g. diuretic
rugs, carperitide, angiotensin-converting enzyme (ACE)
nhibitors, and -blockers) were recommended for use.
T-pro-BNP and BNP measurement
lood sampling was performed on admission (Day 1), and
n Days 3, and 7 of hospitalization, and the serum levels
f BNP and NT-pro-BNP were measured to evaluate the efﬁ-
iency of nicorandil. The blood samples were collected into
ubes containing EDTA within 30min of admission (Day 1)
nd at each sampling point, and centrifuged immediately.
he serum levels of BNP and NT-pro-BNP were measured
y chemiluminescent immunoassay (CLEIA) as recommended
y the manufacturer (Special Reference Laboratory, SRL©,
okyo, Japan). The normal ranges of values published by a
revious study were as follows: as a general guideline, in
oung healthy adults, 90% will have a BNP <25 pg/ml and
NT-pro-BNP <70 pg/ml [14]. In acutely dyspneic patients,
ome have suggested cutoffs of BNP <100 pg/ml and NT-pro-
NP <300 pg/ml to rule out HF [8,15]. Serum levels of BNP
nd NT-pro-BNP were compared for both groups. Samples
ere obtained from all 31 patients on Day 1, Day 3, and Dayransthoracic echocardiography was performed to assess the
VEF, end diastolic (systolic) volume (ED(S)V) and left ven-
ricular end diastolic/systolic dimension (LVDd(s)) before
ute h
p
i
R
P
h
T
w
p
i
(
e
e
l
c
i
o
w
i
t
t
c
r
i
t
c
t
w
g
(
f
r
n
M
n
ﬁ
n
a
d
N
T
B
r
r
1
a
n
o
nEfﬁcacy and safety of nicorandil therapy in patients with ac
and from 3 to 7 days after treatment (Vivid I, GE Yokokawa
Medical, Tokyo, Japan). LVEF and ED(S)V were calculated
using the Teicholz or Simpson’s method. Chest X-rays were
also performed to assess the cardiothoracic ratio before
and 3 days and 7 days after treatment. Electrocardiograph
monitoring was continued throughout the treatment period.
All clinical parameters were compared between the nico-
randil and control groups. Echocardiography was performed
on only 24 patients (11 patients from control group and 13
patients from nicorandil group) in an emergency setting. We
were unable to clearly record the dimensions and LVEF from
all AHF patients in the emergency setting with orthopnea.
Hemodynamic measurements
The systolic BP (SBP), diastolic BP (DBP), and heart rate (HR)
were also evaluated as a hemodynamic measurement at 6,
12, 24 h, 3 days, and 7 days after admission. The patients
were further classiﬁed within the nicorandil group into a high
SBP group (baseline SBP >140mmHg, n = 10) and a low SBP
group (baseline SBP <140mmHg, n = 6). The time-dependent
change in SBP was evaluated in both groups to assess the
safety of nicorandil.
End points
The primary end point of the study was to evaluate the
changes in the serum levels of BNP and NT-pro-BNP as the
parameters of cardiac function during nicorandil adminis-
tration, and assess the efﬁcacy of nicorandil. The secondary
end points were to analyze the reason why BNP and
NT-pro-BNP changes during nicorandil administration. We
performed echocardiography to evaluate the difference in
left ventricular geometry, including the left ventricular vol-
ume between the two groups. The third end points were
to evaluate changes in hemodynamic measurement during
nicorandil administration, and assess the safety of nico-
randil.
Statistical analysis
All numerical data are expressed as the means± standard
deviation. Comparisons of all proportions were performed
with a chi-square analysis. The change over time after
admission of BNP and NT-pro-BNP was tested using the
one-way analysis of variance (ANOVA) on repeated mea-
sures. When a signiﬁcant time change was observed,
the levels at individual time points were compared with
Fisher’s protected least signiﬁcant difference (PLSD) post
hoc tests. Unpaired t-tests were used to compare mean val-
ues between the nicorandil and control groups. A p-value of
<0.05 was deﬁned as statistically signiﬁcant.
All data were analyzed using the StatView 5 software pro-
gram for Windows (SAS Institute, Cary, NC, USA), and SPSS
14.0 J for Windows.Ethical concerns
The institutional review board at Chiba Hokusoh Hospital,
Nippon Medical School approved the study protocol. All
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atients provided their written informed consent to partic-
pate in this study.
esults
atient characteristics and medication during
ospitalization
able 1 shows that the patient cohort consisted of 71% males
ith a mean age of 70.1± 13.0 years. Fourteen (45%) of the
atients had ischemic heart disease, and 17 (55%) had non-
schemic heart diseases including dilated cardiomyopathy
n = 4), hypertensive heart disease (n = 7), and valvular dis-
ase (n = 6). The average LVEF determined by transthoracic
chocardiography upon admission was 38.5%. Intravenous
oop diuretics were administered to all AHF patients, and
arperitide was administered to 86.7% of the patients dur-
ng the acute phase, whereas nitroglycerin was used in 54.8%
f the patients. In contrast, dopamine and dobutamine
ere used in 9.7% and 19.4% of patients, respectively. ACE
nhibitors or angiotensin II receptor blockers (ARB) had been
aken by 17 patients (54.8%), while -blockers had also been
aken by 17 patients (54.8%) during hospitalization. Table 1
ompares the backgrounds of the patients in the nico-
andil and control groups. There were no major differences
n the patients’ backgrounds in the two groups. However,
he serum levels of potassium on admission were signiﬁ-
antly higher in the nicorandil group (4.83± 0.59mmol/l)
han in the control group (4.06± 0.48mg/dl) (p < 0.05),
hereas sodium levels tended to be lower in the nicorandil
roup (138.0± 3.7mmol/l) compared with control group
140.5± 3.4mmol/l) (p = 0.06). Nitroglycerin was used less
requently during the acute phase in the patients in the nico-
andil group, but there were no signiﬁcant differences in the
itroglycerin use between the two groups (p = 0.09).
The clinical proﬁle of the 31 patients is shown in Table 2.
ost patients were in NYHA class IV (84%), and had orthop-
ea (90%) and rales (97%) at admission. The rate of physical
ndings, including paroxysmal nocturnal dyspnea, orthop-
ea, rales, third heart sound, jugular venous distension,
nd peripheral edema at admission were not substantially
ifferent between the two groups.
T-pro-BNP, BNP and nicorandil therapy
here were no differences in the serum levels of
NP and NT-pro-BNP on Day 1 between the nico-
andil group (1397.0± 1617.5, 11,270.0± 12,388.5 pg/ml,
espectively) and the control group (1072.7± 988.8,
0,608.4± 12,506.8 ng/ml, respectively), nor were there
ny differences at other sampling points (Table 3). BNP sig-
iﬁcantly decreased in the patients in the nicorandil group
n Day 3 and Day 7 (p < 0.05; Fig. 1A), however, there were
o signiﬁcant decreases in patients in the control group on
ay 3 or Day 7 (Fig. 1A). NT-pro-BNP tended to decrease
n Day 3 (p = 0.06), and also signiﬁcantly decreased in the
icorandil group on Day 7, however there were no changes
n the control group on any of the days compared to Day 1
Fig. 1B).
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Table 1 Comparison of the patients’ background and the progress during hospitalization in the control group and the nicorandil
group.
Control group (n = 15) Nicorandil group (n = 16) All patients (n = 31) p-Value
Age (years) 70.3± 12.6 75.0± 8.3 70.1± 13.0 0.23
Past medical history
Hypertension (y/n) 12/3 13/3 25/6 0.99
Diabetes mellitus (y/n) 6/9 7/9 13/18 0.99
Dyslipidemia (y/n) 10/5 9/7 19/12 0.81
Type (new onset/worsening) 4/11 6/10 10/21 0.79
Etiology (ischemia/non-ischemia) 7/8 7/9 14/17 0.99
Gender (male/female) 9/6 13/3 22/9 0.36
NYHA (III/IV) 2/13 3/13 5/26 0.99
BUN (mg/dl) 28.8± 18.4 27.4± 14.0 28.1± 16.1 0.81
Creatinine (mg/dl) 1.60± 1.65 1.42± 0.89 1.51± 1.29 0.72
Total bilirbin (mg/dl) 0.58± 0.21 0.66± 0.34 0.62± 0.28 0.45
Urinary acid (mg/dl) 6.55± 1.69 6.84± 1.47 6.70± 1.55 0.63
Sodium (mmol/l) 140.5± 3.4 138.0± 3.7 139.2± 3.7 0.06
Potassium (mmol/l) 4.06± 0.48 4.83± 0.59 4.45± 0.66 <0.05
Hemoglobin (g/dl) 12.6± 3.4 12.3± 2.3 12.4± 2.8 0.76
Systolic blood preasure (mmHg) 172.5± 38.7 169± 39.4 175.4± 41.1 0.79
Pulse (beats/min) 116.5± 23.1 114.8± 19.9 117.7± 22.5 0.83
LVEF (%) on admission 38.0± 19.3 39.0± 17.8 38.5± 13.3 0.88
Medication during hospitalization
Furosemide (y/n) 15/0 16/0 31/0 0.99
Nitroglycerin (y/n) 11/4 6/10 17/14 0.09
Carperitide (y/n) 14/1 14/2 28/3 0.99
Dopamine (y/n) 3/12 0/16 3/28 0.20
Dobutamine (y/n) 3/12 3/13 6/25 0.99
ACE-I/ARB (y/n) 9/6 8/8 17/14 0.83
-blocker (y/n) 7/8 10/6 17/14 0.59
Statin (y/n) 6/9 11/5 17/14 0.21
Spironolactone (y/n) 6/9 6/10 12/19 0.99
Total admittance (days) 49.1± 56.2 29.9± 23.9 39.2± 43.1 0.24
Prognosis during admission
Alive/dead 13/2 15/1 28/3 0.60
y/n, yes/no; NYHA, New York Heart Association; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction measured by echocar-
diogram on admission; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
p-Value for between-group comparisons.
Table 2 Comparison of the clinical proﬁle at admission in the control group and the nicorandil group.
Control group (n=15) Nicorandil group (n = 16) All patients (n = 31) p-Value
NYHA (III/IV) 2/13 3/13 5/26 0.99
Physical ﬁndings
Paroxysmal nocturnal dyspnea (y/n) 3/12 5/11 8/23 0.59
Orthopnea (y/n) 14/1 14/2 28/3 0.99
Rales (y/n) 14/1 16/0 30/1 0.99
Third heart sound (y/n) 10/5 8/8 18/13 0.87
Jugular venous distension (y/n) 6/9 5/11 11/20 0.99
Peripheral edema (y/n) 6/9 3/13 9/22 0.49
Cold extremities (y/n) 4/11 3/13 7/24 0.99
Noninvasive hemodynamic assessments
Warm and wet/cold and wet 12/3 13/3 25/6 0.99
y/n, yes/no; NYHA; New York Heart Association.
p-Value for between-group comparisons.
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Table 3 Serum levels of BNP and NT-pro-BNP in the control group and the nicorandil group.
Control group (n = 15) Nicorandil group (n = 16) p-Value
BNP (pg/ml)
Day 1 1072.7 ± 988.8 1397.0 ± 1617.5 0.504
Day 3 661.0 ± 654.0 502.4 ± 406.9 0.429
Day 7 1035.2 ± 1749.0 463.2 ± 355.3 0.232
NT-pro-BNP (pg/ml)
Day 1 10,608.4 ± 12506.8 11,270.0 ± 12,388.5 0.883
Day 3 89,28.3 ± 12375.5 7316.7 ± 10,187.5 0.696
Day 7 9696.6 ± 13482.3 5702.9 ± 6468.8 0.311
BNP, brain natriuretic peptide; NT-pro-BNP, N-terminal pro brain natriur
day 3; Day 7, on hospital day 7.
p-Value for between-group comparisons.
Figure 1 Time-dependent changes in serum BNP and NT-pro-
BNP after treatment for AHF. (A) The serum level of BNP was
signiﬁcantly decreased on Day 3 compared to Day 1 and there-
after the level reached a plateau in the nicorandil group. (B)
The serum level of NT-pro-BNP also tended to be decreased on
Day 3, and was signiﬁcantly decreased on Day 7 compared to
Day 1 in the nicorandil group. Thereafter, the level reached
a plateau. Values are expressed as the means± SD. *p < 0.05 in
comparison to Day 1 on each group. BNP, B-type natriuretic pep-
tide; NT-pro-BNP, N-terminal pro-BNP; Day 1, within 30min of
admission; Day 3, on hospital day 3; Day 7, on hospital day 7.
C
T
p
d
O
c
a
t
e
g
e
c
i
b
b
c
t
E
t
t
i
w
t
H
S
i
s
b
f
h
p
t
D
N
d
n
m
cetic peptide; Day 1, within 30min of admission; Day 3, on hospital
linical evaluation
he physical ﬁndings including paroxysmal nocturnal dys-
nea, orthopnea, third heart sound, and jugular venous
istension improved in all patients at 7 days after treatment.
n the other hand, rales remained in four patients from the
ontrol group and in one patient from the nicorandil group
t 7 days after treatment. Peripheral edema also continued
o be observed in two patients from the control group, how-
ver, it was not found in any patients from the nicorandil
roup.
Table 4 shows the changes in the chest X-ray and
chocardiographic parameters between the two groups. The
ardiothoracic ratio on chest X-rays signiﬁcantly decreased
n both groups on Day 7. LVEF signiﬁcantly increased from
efore treatment to after treatment in the nicorandil group,
ut no difference was seen in the control group. The delta
hanges (changes in LVDd from after treatment to before
reatment) of LVDd were shorter and the delta changes of
DV were smaller in the nicorandil group, but it was not sta-
istically different, respectively. The delta changes of LVDs
ended (p = 0.08) to be shorter in the nicorandil group than
n the control group, furthermore the delta changes of ESV
ere signiﬁcantly (p < 0.05) smaller in the nicorandil group
han in the control group.
emodynamic measurement
BP decreased signiﬁcantly after 6 h and reached a plateau
n both groups (Fig. 2A), and the DBP and HR also decreased
igniﬁcantly 6 h after admission and reached a plateau in
oth groups (Table 5). SBP showed a signiﬁcant decrease
rom before treatment to after treatment not only in the
igh SBP group (from 190.0± 35.1 to 121.6± 25.0mmHg,
< 0.0001), but also in the low SBP group (from 133.6± 7.74
o 108.7± 15.7mmHg, p < 0.05) (Fig. 2B and C).
iscussionicorandil is an optimal treatment for improving the hemo-
ynamics in patients with chronic HF [3,4]. In addition,
icorandil can increase coronary perfusion [16], and has pri-
arily been used clinically in Japan in patients with acute
oronary syndrome. However, nicorandil has so far only been
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Table 4 Changes in the chest X-ray and echocardiographic parameters in the nicorandil group and control group.
n Control group n Nicorandil group p-Value
Chest X-ray
Cardiothoracic ratio (%)
Before treatment 15 62.3 ± 3.9 16 60.8 ± 8.9 0.55
3 days after treatment 15 62.1 ± 3.3 16 59.9 ± 8.1 0.34
7 days after treatment 15 58.2 ± 5.7* 16 57.1 ± 7.7* 0.66
Echocardiography
LVEF (%)
Before treatment 11 38.1 ± 18.9 13 39.0 ± 17.8 0.89
After treatment 11 42.6 ± 18.5 13 47.2 ± 16.6* 0.53
LVDd (mm)
Before treatment 11 51.0 ± 13.4 13 51.3 ± 15.3 0.59
After treatment 11 57.8 ± 11.2 13 55.2 ± 8.7 0.68
Delta changes 11 2.1 ± 8.3 13 -0.4 ± 8.6 0.58
LVDs (mm)
Before treatment 11 40.2 ± 15.0 13 42.5 ± 15.9 0.99
After treatment 11 42.7 ± 14.3 13 42.1 ± 10.6 0.92
Delta changes 11 1.1 ± 5.7 13 -4.3 ± 7.8 0.08
EDV (ml)
Before treatment 11 132.9 ± 54.7 13 145.6 ± 67.5 0.59
After treatment 11 157.2 ± 69.4 13 149.2 ± 53.8 0.75
Delta changes 11 18.9 ± 42.2 13 -5.6 ± 54.0 0.24
ESV (ml)
Before treatment 11 82.7 ± 52.2 13 104.7 ± 49.8 0.28
After treatment 11 101.8 ± 62.7 13 86.2 ± 45.6 0.49
Delta changes 11 14.8 ± 41.8 13 -22.0 ± 43.3 0.04
LVEF, left ventricular ejection fraction; LVDd(s), diastolic (systolic) left ventricular diameter; ED(S)V, end diastolic (systolic) volume.
eatm
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tDelta changes mean the change in LVDd(s) and ED(S)V from after tr
After treatment means 3—7 days after admission.
* p < 0.05 compared with before treatment and after treatment
dministered to a few patients with AHF in Japan. ATTEND
egistry showed that only 10.6% of AHF patients used nico-
andil as a vasodilator [17]. Nicorandil might be useful in
atients with AHF, since it can reduce the preload and
fter-load, while increasing coronary perfusion. Almost all
f these patients experience relative myocardial ischemia
uring the acute phase and coronary artery spasm during
he acute phase might cause transient HF [18]. Therefore,
icorandil has been approved for use since 2007 in Japan
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Table 5 Changes in the hemodynamic measurements in the nico
Before treatment After treatment
6 h 12 h
SBP (mmHg)
Control 176.4 ± 37.7 128.7 ± 26.8 128.4 ±
Nicorandil 168.8 ± 39.4 124.3 ± 22.5 124.3 ±
DBP (mmHg)
Control 90.7 ± 18.1 63.2 ± 11.0 61.6 ±
Nicorandil 90.3 ± 22.1 68.6 ± 14.7 65.9 ±
HR (mmHg)
Control 115.9 ± 23.1 86.4 ± 14.1 80.9 ±
Nicorandil 114.1 ± 19.4 86.5 ± 13.1 82.9 ±
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart raent to before treatment; p-value for between-group comparisons.
or patients with AHF, however, the potential usefulness of
icorandil in these patients has not yet been thoroughly
xamined.
Our current ﬁndings suggest that intravenous administra-
ion of nicorandil can decrease the serum levels of BNP and
T-pro-BNP in patients with AHF during the acute phase.
oreover, serum levels of BNP were decreased more on Day
and the levels of NT-pro-BNP were decreased more on
ay 7 in the patients in the nicorandil group compared with
randil group and the control group.
24 h 3 days 7 days
26.8 122.0 ± 21.9 126.3 ± 24.1 120.7 ± 18.9
22.5 123.4 ± 19.9 116.8 ± 22.4 120.9 ± 20.3
13.9 61.8 ± 10.8 62.3 ± 5.7 64.9 ± 14.1
15.9 60.0 ± 11.1 60.1 ± 12.8 62.6 ± 8.9
15.7 82.1 ± 13.9 83.7 ± 13.5 78.8 ± 9.1
15.2 84.3 ± 16.0 82.9 ± 13.8 75.2 ± 11.6
te.
Efﬁcacy and safety of nicorandil therapy in patients with acute h
Figure 2 Time-dependent changes in systolic blood pressure
(SBP). (A) SBP signiﬁcantly decreased on Day 3 compared to Day
1, and reached a plateau in patients in both the nicorandil and
control groups. (B) The SBP was signiﬁcantly decreased on Day
3 by the nicorandil therapy in the high SBP group (p < 0.0001).
(C) The SBP was also decreased on Day 3 by the nicorandil ther-
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nicorandil therapyapy in the low SBP group (p < 0.05). Patients were not exposed
to excessive hypotension following the administration of nico-
randil.
those in the control group. Regarding the mechanism of BNP
and NT-pro-BNP reduction, our echocardiographic ﬁndings
suggest that nicorandil might be able to reduce the ﬁlling
volume, while also improving LVEF during the acute phase.
Nicorandil could also reduce the SBP in patients with a low
SBP without exposing hypotension, thus indicating that it
can be safely administered to patients with a low SBP.
BNP and NT-pro-BNP in patients with AHF
The measurement of serum BNP, which is secreted by the
heart in response to increases in ﬁlling pressure, has been
used for approximately two decades in patients with con-
gestive HF in outpatient departments [10]. When the heart
experiences volume expansion or pressure overload, the
resulting wall stress initiates the synthesis of pro-BNP in
the ventricular and atrial myocardium [10]. BNP is synthe-
sized as pro-BNP in cardiac myocytes, and then pro-BNP is
transformed into the hormonally active BNP and inactive NT-
pro-BNP. BNP and NT-pro-BNP are thought to be secreted
from the heart in equimolar amounts [10], and pro-BNP is
also secreted into the blood stream. Pro-BNP, BNP, and NT-
pro-BNP therefore can be detected in the plasma. Among the
three molecular forms, serum levels of BNP and NT-pro-BNP
N
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ere thought to be inﬂuenced by ventricular end diastolic
ressure and LVEF in patients with chronic HF [12,13]. In the
resent study, it is difﬁcult to speculate regarding the rea-
on why nicorandil signiﬁcantly decreased the serum levels
f BNP and NT-pro-BNP. As one possibility from echocardio-
raphic assessments, nicorandil might be able to reduce the
olume expansion and improve the systolic function during
he acute phase.
Serum levels of BNP and NT-pro-BNP rise to very high lev-
ls during AHF, so rapid measurement of BNP and NT-pro-BNP
n the emergency department has been shown to be useful
n differentiating dyspnea due to AHF from dyspnea related
o other factors [7,8], and testing for BNP and NT-pro-BNP
evels is recommended in the guidelines as class I [9]. In
he present study, the serum levels of BNP and NT-pro-BNP
ere excessively above the normal ranges in all patients
ith AHF on Day 1. Performance characteristics for BNP and
T-pro-BNP are similar in many clinical scenarios. Although
he data are not shown, the levels showed reasonably good
orrelations for each of the sampling points.
harmacological characteristics of nicorandil
icorandil has two cellular mechanisms of action, acting
oth as an adenosine triphosphate-sensitive potassium chan-
el activator and exhibiting a nitrate-like effect [2,5,19].
icorandil therefore reduces preload and after-load, and
eads the hemodynamic response. Nicorandil is weakly
ound to plasma proteins, and after continuous intravenous
nfusion, steady-state plasma concentrations are reported
o be achieved after 3—6h of continuous infusion [20].
herefore, the intravenous bolus administration was per-
ormed, followed by subsequent continuous administration,
hich was performed for ﬁve days.
Intravenous bolus doses of 251g/kg signiﬁcantly
ecreased pulmonary capillary wedge pressure with
ncreases in the cardiac index, reﬂecting the balanced
rterial and venous effects of nicorandil on the circula-
ion without compromising the SBP [3]. Another report
ndicated that this effect can be achieved by using a load-
ng dose of 200g/kg and maintaining an infusion rate of
00g/kg/h [5]. With these doses, estimated pulmonary
apillary wedge pressure was reduced by 25% without induc-
ion of hypotension. In the present study, nicorandil was
tarted at a lower dose than this previous study, with a
olus injection of 100g/kg, and then continuous injection
f 60—100g/kg/h. In spite of the lower dose, we observed
reduction of the ﬁlling volume with increases in the LVEF
ased on the ﬁndings of echocardiography. The safety of
icorandil was also demonstrated because the intravenous
dministration of nicorandil did not induce hypotension,
hile it signiﬁcantly reduced the SBP in patients with a low
BP. In addition, nicorandil signiﬁcantly reduced the SBP in
atients with a high SBP, in spite of the use of low doses.
he use of other vasodilators in combination withitrates have been used in cardiovascular therapy for more
han one hundred years, and are commonly intravenously
nfused in patients with congestive HF to achieve acute
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eductions in ﬁlling pressure [21]. Nitrates are therefore the
old standard of therapy as vasodilators for AHF. Organic
itrates are believed to primarily dilate the venous system
ather than the arterioles. In contrast, nicorandil can pro-
uce optimal beneﬁts by achieving balanced venous and
rterial vasodilation, and reduced systemic vascular resis-
ance. Thus, hypotension was induced in some cases by
he use of nitrate. In the present study, we experienced
ypotension after using nitroglycerin. On the other hand,
icorandil can be administered in relatively low BP patients
nd therefore can be used safely with carperitide. Carper-
tide was used in 14 patients (88%) in the nicorandil group.
here is a lot of evidence supporting the use of carperi-
ide in patients with AHF during the acute phase [22], and
e should use carperitide and nicorandil together. A previ-
us case report also recommended the combined therapy of
arperitide and nicorandil for patients with AHF [23].
Substantial hemodynamic tolerance to continuous intra-
enous nitrates often develops in patients with congestive
F, requiring sustained vasodilation [24]. However, substan-
ial hemodynamic tolerance to nicorandil did not develop
4]. In fact, Larsen et al. reported a double-blind random-
zed study that demonstrated that intravenous nicorandil
dministration resulted in a signiﬁcantly decreased devel-
pment of hemodynamic tolerance over a 24-h period than
itroglycerin [25]. In the present study, although it was not
igniﬁcantly different, nitroglycerin was used less during the
cute phase by the patients receiving nicorandil for ﬁve
ays. Another drug, nitroprusside, also has balanced effects,
ilating both arterioles and veins. A recent study demon-
trated that patients treated with nitroprusside achieved
reater improvements in hemodynamic measurements dur-
ng hospitalization, and lower rates of all causes of mortality
han in control patients [26]. However, because of the risk of
nduction of hypotension, intravenous nitroprusside is usu-
lly not recommended, and this is the reason why it was not
sed in the present study.
tudy limitations
here are several limitations to this study. First, the tissue
oncentrations of BNP and NT-pro-BNP were not evaluated.
espite some evidence of increased tissue BNP in animal
odels of HF, information concerning the dynamic changes
f tissue BNP and NT-pro-BNP during the acute phase of
F is limited. Previous studies have demonstrated that the
yocardium is an important source of changes in the plasma
oncentrations of BNP and NT-pro-BNP in stable congestive
F [12]. On that basis, the present study considered only the
oncentrations of circulating BNP and NT-pro-BNP. Moreover,
he value of BNP and NT-pro-BNP as a diagnostic guide for
he treatment of AHF remains quite controversial. Second,
here was no limitation in the use of other HF therapies,
nd the treatment strategy was left to the attending physi-
ian’s discretion. All of the effective treatments for AHF
e.g. diuretic drugs, carperitide, nitrate, ACE inhibitors, and
-blockers) were recommended for use. Therefore, vari-
us drugs were co-administered in both groups, and it was
mpossible to identify the effect of nicorandil alone from
hose of concomitant therapies that all patients were receiv-
ng. The serum levels of BNP and NT-pro-BNP might alsoA. Shirakabe et al.
ave been inﬂuenced by these treatments. Third, only two
ardiac markers were evaluated. The evaluation of more
arkers may have more clearly delineated the efﬁcacy of
his treatment for patients with AHF. Fourth, we were unable
o determine the changes in the left ventricular geometry,
ncluding the left ventricular volume clearly from all AHF
atients. Twenty-four patients could undergo transthoracic
chocardiography at the time of admission, however it was
ifﬁcult to compare these data with the data after HF was
tabilized because they were recorded under different con-
itions. We were unable to clearly record the dimensions
n the emergency setting with orthopnea. Finally, the main
imitation of the study was the small number of patients
ncluded in each group. Therefore, some patient bias might
xist between the nicorandil group and the control group. As
result, our conclusion that the administration of nicorandil
s effective during the acute phase in patients with AHF may
e somewhat premature. These ﬁndings therefore remain
o be conﬁrmed in a larger, well-controlled, randomized
linical trial.
In conclusion, in addition to conventional HF therapy, the
arly intravenous administration of nicorandil in patients
ith AHF signiﬁcantly decreased BNP and NT-pro-BNP, with-
ut any signiﬁcant adverse effect on BP in patients with low
BP.
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